2014-08-08T07:50:41-05:00 2013-12-31 521855942 TATE AND TRYON 2021 L STREET NW SUITE 400 WASHINGTON DC 20036 990 2013-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 PAUL AINES CPA, CFO 5714831300 2014-08-08 1 DEBORAH G KOSNETT P00290720 2022932200 2013 2015-11-30 17:44:51Z ASCO ALLEN LICHTER MD 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 170422642 0 X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, CONTINUED FROM PAGE 1: PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 18 17 403 1200 14383866 3403799 9951001 8477875 73138765 76312383 4566995 6859928 771150 1351743 88427911 93001929 1729260 1103926 0 0 31364730 30968009 110025 0 2992820 44890049 47687206 78094064 79759141 10333847 13242788 177197733 195594554 104485526 98271504 72712207 97323050 X ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY CARE.ASCO VISION STATEMENTS:-- ALL CANCER PATIENTS WILL HAVE LIFELONG ACCESS TO HIGH QUALITY, EFFECTIVE, AFFORDABLE AND COMPASSIONATE CARE.-- THE MOST ACCURATE CANCER INFORMATION WILL BE AVAILABLE SO THAT PATIENTS AND PHYSICIANS CAN MAKE INFORMED DECISIONS ABOUT CANCER PREVENTION AND TREATMENT.-- INFORMATION WE LEARN FROM EVERY PATIENT WILL BE USED TO ACCELERATE PROGRESS AGAINST CANCER.-- RESOURCES WILL EXIST TO ATTRACT THE BEST CLINICIANS AND INVESTIGATORS TO PROVIDE OPTIMAL PATIENT CARE AND TO CONDUCT TRANSFORMATIVE RESEARCH. --ASCO WILL BE RECOGNIZED AS THE MOST TRUSTED SOURCE OF CANCER INFORMATION WORLDWIDE. 0 0 32812833 422256 46730363 EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS AND PROFESSIONAL DEVELOPMENT: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCE KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE.THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE EDUCATIONAL NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND ASSIST THEM IN PROVIDING WORLD CLASS CANCER CARE AND IN CONDUCTING CUTTING EDGE RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS,JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY.WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM.ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS.HIGHLIGHTS OF THE 2013 ACTIVITIES INCLUDE: OVER 32,000 PEOPLE ATTENDED THE 2013 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES, CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2013 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2013 ANNUAL MEETING FEATURED OVER 220 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 4,500 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY.-IN 2013, ASCO HELD THREE "BEST OF ASCO" MEETINGS, WHICH COVERED THE MOST GROUND BREAKING SCIENCE RELEASED AT ASCO'S ANNUAL MEETING. OVER 1,200 ATTENDEES PARTICIPATED IN THESE MEETINGS.-IN 2013, ASCO OFFERED ITS SECOND QUALITY CARE SYMPOSIUM, WITH NEARLY 650 PEOPLE IN ATTENDANCE.-IN 2013, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD, WHICH COLLECTIVELY DREW NEARLY 6,500 ATTENDEES. ALL 2013 ASCO MEETINGS AND SYMPOSIA WERE OPEN TO THE GENERAL PUBLIC. THESE MEETINGS INCLUDE:- ANNUAL MEETING- BEST OF ASCO CHICAGO- BEST OF ASCO BOSTON- BEST OF ASCO LOS ANGELES- ASCO'S QUALITY CARE SYMPOSIUM- GI CANCERS SYMPOSIUM- GU CANCERS SYMPOSIUM- BREAST CANCER SYMPOSIUM- ASCO/AACR METHODS IN CLINICAL CANCER RESEARCH WORKSHOPINTERNATIONAL AFFAIRS MEETINGS AND COURSES- BEST OF ASCO INTERNATIONAL (24)- JOINT SYMPOSIA (16)- ADVANCED CANCER COURSES (8)- MULTIDISCIPLINARY CANCER MANAGEMENT COURSES (4)ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS ENHANCED COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. 10670552 138150 28754848 EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES TWO EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. THE JOURNALS INCLUDE ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS, AND OTHER WORK THAT RELATES TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THEREBY INCREASING ITS USE INTERNATIONALLY.-IN 2013 JOURNAL OF CLINICAL ONCOLOGY HAD 26,340 ANNUAL SUBSCRIBERS. ADDITIONALLY, AS REPORTED BY THOMSON REUTERS IN ITS 2011 JOURNAL CITATION REPORT, JCO'S IMPACT FACTOR OF 18.732 RANKED IT #53 OUT OF 8,336 JOURNALS MEASURED AND #5 IN THE ONCOLOGY CATEGORY (196 JOURNALS MEASURED). JCO RECEIVED 120,262 TOTAL CITATIONS IN 2011, WHICH RANKED IT #23 OVERALL AND #2 IN THE ONCOLOGY CATEGORY. JCO'S EIGENFACTOR SCORE OF 0.39463 (A MEASURE OF WHAT TYPES OF CITATIONS WERE GENERATED) RANKED IT #16 OVERALL AND #1 IN THE ONCOLOGY CATEGORY. THE IMPACT FACTOR, TOTAL CITATIONS, AND EIGENFACTOR SCORES ARE ALL REFLECTIONS OF THE VALUE RESEARCHERS FIND IN JCO CONTENT. ALL JCO ARTICLES ARE AVAILABLE FREE TO THE GENERAL PUBLIC ONE YEAR AFTER PUBLICATION. CERTAIN ARTICLES ARE AVAILABLE IMMEDIATELY, AND MANY ARTICLES ARE AVAILABLE THROUGH THE PUBLIC LIBRARY OF SCIENCE, A REPOSITORY OF SCIENTIFIC AND MEDICAL LITERATURE THAT IS FREELY ACCESSIBLE TO SCIENTISTS AND THE PUBLIC.IN 2013, JOURNAL OF ONCOLOGY PRACTICE (JOP) WAS ACCEPTED FOR INDEXING IN MEDLINE, THE PREMIER BIBLIOGRAPHIC DATABASE OF THE U.S. NATIONAL LIBRARY OF MEDICINE (NLM). THE INCLUSION OF JOP IN MEDLINE GIVES AN INDICATION OF ITS GROWING PROMINENCE AND REPUTATION IN ONCOLOGY AND IS A REFLECTION OF THE VERY HIGH QUALITY OF ITS PUBLISHED ARTICLES. 7612826 19250 233885 QUALITY: THE ASCO QUALITY DEPARTMENT IS RESPONSIBLE FOR THE DEVELOPMENT OF EVIDENCE-BASED GUIDELINES, DEVELOPING AND VALIDATING QUALITY MEASURES IN ONCOLOGY, QUALITY IMPROVEMENT AND MEASUREMENT.IN 2013, ASCO, WITH ITS RELATED ORGANIZATION, ASCO INSTITUTE FOR QUALITY, LLC, ENTERED THE ASSESSMENT PHASE OF CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. THE ASSESSMENT PHASE FOCUSES ON THE DEVELOPMENT OF A BREAST-CANCER SPECIFIC PROTOTYPE, WHICH WILL HELP DETERMINE AND OVERCOME THE BARRIERS IN DEVELOPING A FULL SYSTEM. PROGRAMS INCLUDE:- QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI), A VOLUNTARY QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING PRACTICES IN HAWAII, ALASKA, GUAM, AND PUERTO RICO ARE ENROLLED IN THE PROGRAM.- QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE IMPACT OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE.THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO:- PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS.- PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES.- REDUCE REDUNDANT PROGRAMS RELATED TO THE DEMONSTRATION OF QUALITY. THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A SPECIAL-PURPOSE LIMITED LIABILITY CORPORATION (LLC), ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM). THE SOLE MEMBER OF THIS LLC IS ASCO AND THE PRESIDENT IS ASCO'S CHIEF EXECUTIVE OFFICER. NEW GUIDELINES AND ONGOING UPDATES. ASCO NOW HAS 39 PUBLISHED PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. AN ADDITIONAL 11 GUIDELINES ARE IN DEVELOPMENT, ALONG WITH 6 UPDATES TO EXISTING GUIDELINES. IN ADDITION, ASCO HAS ENDORSED 2 GUIDELINES DEVELOPED BY OUTSIDE ORGANIZATIONS. 14463009 524270 593287 CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE IN ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, FEDERAL HEALTH PROGRAMS, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS TO CARE, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY.CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE.IN 2013, ASCO'S ACTIVITIES INCLUDED EFFORTS IN THE FOLLOWING AREAS:- BROAD EFFORTS TO BETTER STEWARD LIMITED HEALTH CARE RESOURCES INCLUDING ASCO PARTICIPATION IN SECOND ROUND OF THE AMERICAN BOARD OF INTERNAL MEDICINE'S "CHOOSING WISELY" CAMPAIGN, WHICH IS AIMED AT REDUCING OR ELIMINATING COMMONLY USED SERVICES THAT ARE OF QUESTIONABLE VALUE. ASCO'S COST OF CARE TASK FORCE COLLABORATES WITH QUALITY AND EDUCATION TEAMS TO DISSEMINATE RECOMMENDATIONS TO ONCOLOGISTS. ASCO CONTINUED ITS POLICY WORK IN 2013 BY ADDRESSING CANCER CARE AND RESEARCH ISSUES IN THE AREAS OF SURVIVORSHIP, TOBACCO USE, HEREDITARY CANCER RISK, AND CARE FOR PATIENTS WITH ADVANCED CANCER. ALSO, AS PART OF A COMPREHENSIVE EFFORT TO DETERMINE WORKFORCE CAPACITY TO MEET PROJECTED INCREASES IN CANCER INCIDENCE AND TO IDENTIFY INNOVATIVE CARE MODELS, ASCO STEWARDED A MULTI-PRONGED RESEARCH EFFORT TO ESTABLISH AN ONCOLOGY CENSUS, IDENTIFY TRENDS IN PRACTICE ECONOMICS, AND DOCUMENT CARE PATTERNS. ASCO WORKED WITH OTHER ADVOCACY GROUPS TO COMMUNICATE WITH THE DEPARTMENTS OF HEALTH AND HUMAN SERVICES, TREASURY, AND LABOR TO ENCOURAGE COMPREHENSIVE IMPLEMENTATION OF THE CLINICAL TRIALS COVERAGE PROVISION OF THE AFFORDABLE CARE ACT. FINALY, THE SOCIETY WORKED IN COLLABORATION WITH FDA AND OTHER ONCOLOGY STAKEHOLDERS TO REFINE CLINICAL ENDPOINTS USED IN CANCER CLINICAL TRIALS, OPTIMIZE DATA COLLECTION FOR SUPPLEMENTAL DRUG APPLICATIONS, AND TO ADDRESS THE ONGOING CHALLENGES PRESENTED BY PERSISTENT SHORTAGES OF CRITICAL CHEMOTHERAPY DRUGS.THE STATE/REGIONAL AFFILIATE PROGRAM:THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL.FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCHASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH (NIH). STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC).ORIGINAL DATA COLLECTIONASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. IN 2013, ASCO COMPLETED A WORKFORCE CENSUS AND A COMPREHENSIVE ASSESSMENT OF EMERGING ONCOLOGY PRACTICE TRENDS. TO CLOSELY MONITOR THE RESEARCH AND PRACTICE ENVIRONMENTS AND PROVIDE AN IMPORTANT FOUNDATION FOR DETERMINING IMPACT OF CHANGES OCCURRING AS A RESULT OF HEALTHCARE REFORM IN THE UNITED STATES.MEMBER RELATIONS AND INFORMATIONASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 34,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND ANSWERING MEMBER REQUESTS FOR INFORMATION, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS.ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES, TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CUTTING EDGE RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AND OPPORTUNITIES TO CREATE GROUPS.COMMUNICATIONS AND PATIENT INFORMATION:ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA, AND HEALTH CARE PROFESSIONALS THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER.IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), AND BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET.ASCO ALSO PROVIDES THE FOLLOWING INFORMATIONAL SERVICES TO THE PUBLIC:FIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST. CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA.WHAT TO KNOW: ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS.RESEARCH AND MEETINGS: INFORMATION ON ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS.MULTIMEDIA: MEDICAL ILLUSTRATIONS, MOBILE APPS, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING.EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH.CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT.ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS.CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, SURVIVORSHIP, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. 14463009 524270 593287 65559220 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 1 0 1 0 1 1 1 1 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1 392 0 1 403 1 1 1 0 0 0 0 0 0 0 0 0 X 18 17 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 VA NY X PAUL AINES CPA CFO 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 CLIFFORD HUDIS MD 09-12 PRESIDENT (12-13) 1.00 1.00 X X 0 0 0 PETER P YU MD 9-13 PRESIDENT ELECT (12-14) 1.00 0.00 X X 0 0 0 SANDRA M SWAIN MD IMMED PAST PRES (13-14) 1.00 0.00 X 0 0 0 SUSAN L COHN MD 09-12 TREASURER (12-14) 1.00 0.00 X X 500 0 0 SMITA BHATIA MD BOARD MEMBER (12-16) 1.00 0.00 X 1500 0 0 GARY COHEN MD BOARD MEMBER (11-14) 1.00 0.00 X 0 0 0 STEPHEN GRUBBS MD BOARD MEMBER (12-15) 1.00 0.00 X 0 0 0 DANIEL HAYES MD BOARD MEMBER (11-14) 1.00 0.00 X 0 0 0 PAULO HOFF MD BOARD MEMBER (13-17) 1.00 0.00 X 0 0 0 HAGOP M KANTARJIAN MD BOARD MEMBER (12-16) 1.00 0.00 X 0 0 0 GARY H LYMAN MD BOARD MEMBER (12-16) 1.00 0.00 X 0 0 0 NEAL J MEROPOL MD BOARD MEMBER (13-17) 1.00 0.00 X 500 0 0 THERESE M MULVEY MD BOARD MEMBER (13-17) 1.00 0.00 X 0 0 0 LORI J PIERCE MD BOARD MEMBER (10-14) 1.00 0.00 X 0 0 0 CAROLYN D RUNOWICZ MD BOARD MEMBER (13-17) 1.00 0.00 X 0 0 0 FRANCES A SHEPHERD MD BOARD MEMBER (10-14) 1.00 0.00 X 500 0 0 LILLIAN L SIU MD BOARD MEMBER (12-16) 1.00 0.00 X 0 0 0 ERIC WINER MD BOARD MEMBER (11-15) 1.00 0.00 X 0 0 0 W CHARLES PENLEY MD CCF CHAIR (NONVOTING) 1.00 0.00 X 0 0 0 ALLEN LICHTER MD CEO, EX OFFICIO DIRECTOR (NONVOTING) 33.50 4.00 X X 784820 0 19955 PAUL AINES CPA CFO 33.50 4.00 X 317000 0 35301 DINA MICHELS ESQ VICE PRES.,GEN COUNSEL,SEC 33.50 4.00 X 478000 0 35007 NANCY DALY MS MPH EXEC DIRECTOR, CCF 1.00 36.50 X 231000 0 28773 JEAN COLVARD S DIR MEMBER & MEETING SVS 37.50 0.00 X 230000 0 21684 DEBORAH KAMIN RN PHD S DIR CANCER POLICY 37.50 0.00 X 246000 0 33957 BERNIE KHOO S DIR INTEGRATED MEDIA 37.50 0.00 X 380481 0 35301 SUZANNE BRACH S DIR MARKETING 37.50 0.00 X 212500 0 27048 KRISTIN LUDWIG S DIR COMMUNICATIONS 37.50 0.00 X 232000 0 17175 KAY NOLL S DIR HUMAN RESOURCES 37.50 0.00 X 201500 0 20472 ROBERT HAUSER PHARMD PHD S DIR QUALITY 37.50 0.00 X 274750 0 35301 RICHARD SCHILSKY MD CHIEF MEDICAL OFCR 37.50 0.00 X 366827 0 28303 3957878 0 338277 64 0 1 0 THE CORKERY GROUP 260 FIFTH AVE NEW YORK NY 10001 PUBLIC RELATIONS 1043275 EKMAN ASSOCIATES 18735 SEABISCUIT RUN YORBA LINDA CA 92886 TECHNOLOGY CONSULTING 582500 MCDERMOTT WILL & EMERY LLP PO BOX 6043 CHICAGO IL 606806043 LEGAL 459798 ASTUTE TECHNOLOGY 11718 BOWMEN GREEN DR RESTON VA 20190 VIDEO RECORDING 454603 SAPIENT CORPORATION PO BOX 4886 BOSTON MA 02212 STRATEGY CONSULTING 272290 15 8371708 56167 50000 8477875 EDUCATION MTGS & PROD 900099 25592471 25592471 ADVERTISING 541800 14650531 14650531 PUBLICATIONS 511190 14104317 14104317 MEMBERSHIP 900099 11626165 11626165 EXHIBITS 900099 9511727 9511727 827172 593287 233885 76312383 3481310 3481310 1515443 1515443 866331 1472227 -605896 -605896 -605896 79327104 75948486 3378618 3378618 3378618 MAILING LIST 511120 336850 336850 OTHER 900099 105346 105346 442196 93001929 61427967 14383866 8712221 X 641269 641269 462657 462657 4026131 3589783 436348 20821009 16774140 4046869 1661592 1400980 260612 2660611 2350409 310202 1798666 1471871 326795 1136093 437545 698548 134350 94110 28823 11417 110663 110663 666260 666260 10948280 9756490 1156497 35293 400268 367719 32549 1807486 1673379 119325 14782 3566532 2768106 756370 42056 4736417 3083702 1311467 341248 2946611 2630848 311099 4664 8155736 7688831 411246 55659 2634769 2104186 275574 255009 439382 382229 29684 27469 PRINTING & PRODUCTION 4331857 4323600 3641 4616 DEVELOPMENT FEE TO CCF 2199996 2199996 POSTAGE & SHIPPING 1791043 1773036 17862 145 UBI TAX 1544931 1544874 30 27 136532 128793 7300 439 79759141 65559220 11207101 2992820 300 300 6772025 4670425 4394111 4931658 3001853 2893602 67539246 13267564 55800602 54271682 104851167 113771697 0 14541834 2377675 513356 177197733 195594554 5034542 4603669 16686023 18956773 38400000 38400000 44364961 36311062 104485526 98271504 X 72712207 97323050 72712207 97323050 177197733 195594554 X 13242788 3314156 8053899 X 0 1 X 1 0 X 9749125 8931139 7731584 9951001 8371708 44734557 57163871 61001326 61722689 60750073 64619271 305257230 155397 235462 386588 345882 336850 1460179 67068393 70167927 69840861 71046956 73327829 351451966 13762781 12940190 10563934 13094217 11456835 61817957 0 13762781 12940190 10563934 13094217 11456835 61817957 289634009 1248387 848971 3354163 3987722 4996753 14435996 1445377 2794100 1677713 1888008 2246507 10051705 2693764 3643071 5031876 5875730 7243260 24487701 73056 73056 69762157 73810998 74872737 76995742 80571089 376012723 0.77030 0.76710 0.06510 0.05650 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 12065 158414 170479 64792774 64963253 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 148210 148941 170099 170479 637729 250000 250000 250000 250000 1000000 1500000 1320 12065 13385 15916 15916 7342677 7342677 48721399 6598341 42123058 11475170 6669223 4805947 54271682 ALPHAKEYS DOUBLE BLACK DIAMOND HEDGE FUND 4325000 F UBS MILLENNIUM FUND OFFSHORE LTD 10216834 F 14541834 LIABILITY UNDER INTEREST RATE SWAP AGREEMENT 10711062 TAXABLE BOND PAYABLE 25600000 36311062 X 105175951 3314156 9526126 12840282 92335669 666260 666260 93001929 80565108 1472227 1472227 79092881 666260 666260 79759141 PART X, LINE 2: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. AT A MINIMUM, THE 2010 THROUGH 2013 TAX YEARS ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: GAIN ON VALUE OF INTEREST RATE SWAP 8,053,899. RENTAL EXPENSES TO PART VIII 1,472,227. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE TO PART VIII 1,472,227. 1 NORTH AMERICA 0 3 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 9984 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 101241 SOUTH AMERICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 121639 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 28923 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 35689 SOUTH ASIA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 13237 RUSSIA & THE NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 28606 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 68770 CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 10216834 0 3 0 0 0 3 408089 10216834 10624923 EUROPE CONTRIBUTION TO SUPPORT INTERNATIONAL CANCER CONTROL. 13368 EUROPE CONTRIBUTION TO SUPPORT INTERNATIONAL CANCER CONTROL. 40800 2 0 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH ASIA 5 5600 CASH/CHECK 21367 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD NORTH AMERICA 2 2200 CASH/CHECK 4567 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD MIDDLE EAST AND NORTH AFRICA 5 5560 CASH/CHECK 19586 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 1 1200 CASH/CHECK 3499 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD RUSSIA & THE NEWLY INDEPENDENT STATES 2 2400 CASH/CHECK 5439 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD EAST ASIA AND THE PACIFIC 4 3500 CASH/CHECK 13227 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SUB-SAHARAN AFRICA 4 4800 CASH/CHECK 17277 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH AMERICA 1 1100 CASH/CHECK 3804 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK 1 0 0 0 0 0 PART I, LINE 2: INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) - THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS OF REVIEW USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, AND TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT AND SUBMIT ONE-YEAR REPORTS. 1 HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW 310 WASHINGTON DC 20036 521485477 501(C)(3) 5000 CONTRIBUTION FRIENDS OF CANCER RESEARCH 3299 K ST NW WASHINGTON DC 20007 521983273 501(C)(3) 20000 CONTRIBUTION AMERICAN COLLEGE OF SURGEONS 633 NORTH ST CLAIR CHICAGO IL 60611 362192800 501(C)(3) 125000 CONTRIBUTION NATIONAL ACADEMY OF SCIENCES 2101 CONSTITUTION AVENUE NW WASHINGTON DC 20418 530196932 501(C)(3) 69000 CONTRIBUTION BROOKINGS INSTITUTION 1775 MASSACHUSETTS AVE WASHINGTON DC 20036 530196577 501(C)(3) 10000 CONTRIBUTION WASHINGTON HOSPITAL CENTER-WASH CANCER INSTITUTE 110 IRVING ST NW WASHINGTON DC 20010 521272129 501(C)(3) 14194 CONTRIBUTION KOMEN NAT'L RACE FOR THE CURE 1911 N FORT MYER DR 112 ARLINGTON VA 22209 751835298 501(C)(3) 25000 CONTRIBUTION CONQUER CANCER FOUNDATION 2318 MILL ROAD 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 140000 CONTRIBUTION MEMORIAL SLOAN KETTERING CANCER CENTER PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 113555 CONTRIBUTION CANCERCARE 275 7TH AVE NEW YORK NY 10001 131825919 501(C)(3) 5000 CONTRIBUTION NATIONAL COALITION FOR CANCER SURVIVORSHIP 1010 WAYNE AVE 770 SILVER SPRING MD 20910 850357897 501(C)(3) 10000 CONTRIBUTION UNIVERSITY OF CHICAGO 1427 E 60TH SUITE 120 CHICAGO IL 60637 362177139 501(C)(3) 28388 CONTRIBUTION AMERICAN ASSOCIATION FOR CANCER RESEARCH 615 CHESTNUT STREET 17TH FLOOR PHILADELPHIA PA 19106 236251648 501(C)(3) 5000 CONTRIBUTION DUKE UNIVERSITY MEDICAL CENTER 2424 ERWIN RD SUITE 601 DURHAM NC 27705 560532129 501(C)(3) 25000 CONTRIBUTION CONTRIBUTION PALO ALTO MEDICAL FOUNDATION 795 EL CAMINO REAL PALO ALTO CA 94301 941156581 501(C)(3) 46132 CONTRIBUTION 15 0 PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO 501(C)(3) ORGANIZATIONS THAT SERVE THE CANCER COMMUNITY. X 1 1 X X X X X X 0 0 0 0 0 0 0 1 1 1 ALLEN LICHTER MD CEO, EX OFFICIO DIRECTOR (NONVOTING) 650820 0 74000 0 60000 0 19125 0 830 0 804775 0 0 0 PAUL AINES CPA CFO 312000 0 5000 0 0 0 19125 0 16176 0 352301 0 0 0 DINA MICHELS ESQ VICE PRES.,GEN COUNSEL,SEC 478000 0 0 0 0 0 19125 0 15882 0 513007 0 0 0 NANCY DALY MS MPH EXEC DIRECTOR, CCF 231000 0 0 0 0 0 17325 0 11448 0 259773 0 0 0 JEAN COLVARD S DIR MEMBER & MEETING SVS 227000 0 3000 0 0 0 16025 0 5659 0 251684 0 0 0 DEBORAH KAMIN RN PHD S DIR CANCER POLICY 241000 0 5000 0 0 0 18075 0 15882 0 279957 0 0 0 BERNIE KHOO S DIR INTEGRATED MEDIA 355000 0 5000 0 20481 0 19125 0 16176 0 415782 0 0 0 SUZANNE BRACH S DIR MARKETING 208000 0 4500 0 0 0 15600 0 11448 0 239548 0 0 0 KRISTIN LUDWIG S DIR COMMUNICATIONS 229000 0 3000 0 0 0 17175 0 0 0 249175 0 0 0 KAY NOLL S DIR HUMAN RESOURCES 197500 0 4000 0 0 0 14813 0 5659 0 221972 0 0 0 ROBERT HAUSER PHARMD PHD S DIR QUALITY 261750 0 13000 0 0 0 19125 0 16176 0 310051 0 0 0 RICHARD SCHILSKY MD CHIEF MEDICAL OFCR 366827 0 0 0 0 0 19125 0 9178 0 395130 0 0 0 PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED TO THE CEO, WHICH IS CONSIDERED PART OF THE CEO'S COMPENSATION AND ADDRESSED IN THE CEO'S WRITTEN EMPLOYMENT CONTRACT. THE HOUSING ALLOWANCE IS TREATED AS TAXABLE COMPENSATION. PART I, LINE 7 PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. PART I, LINE 8 CERTAIN AMOUNTS PAID OR ACCRUED TO THE CEO AND THE VP/GC WERE PURSUANT TO A CONTRACT THAT WAS SUBJECT TO THE INITIAL CONTRACT EXCEPTION DESCRIBED IN TREAS. REGS. SECTION 53.4958-4(A)(3). A INDUSTRIAL DEVELOPMENT AUTHORITY CITY OF ALEXANDRIA 521381432 01530LAD2 2012-08-01 38400000 BUY/BLDOUT 5 FLS HQ BLDG 0 0 0 A 38400000 38400000 2008 0 0 1 1 A 0 0 1 1 0 0.00500 0.00500 0 0 1 A 0 0 0 0 1 1 DEPFA BANK 30.000000000000 0 0 0 0 1 A 1 PART IV, QUESTION 3: ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH DEPFA BANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THESE INTEREST RATE SWAP AGREEMENTS QUALIFY AS A DERIVATIVE INSTRUMENT AND ARE USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2013, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. DURING THE REPORTING YEAR, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THEIR FINAL YEAR OF THEIR BOARD TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCO'S PROFITS OR EXCESS DUES OR A SHARE OF ASCO'S NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP (WITH VOTING RIGHTS) AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR ACTIVE MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G., EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, SERVE ON ALL COMMITTEES OF ASCO, HOLD OFFICE IN ASCO, AND VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS AND CERTAIN COMMITTEE MEMBERS, AS WELL AS APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY, SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 65, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN ALL RIGHTS AND PRIVILEGES OF FULL MEMBER STATUS, EXCEPT THE HOLDING OF OFFICE, INCLUDING THE RIGHT TO ATTEND MEETINGS, SERVE ON ALL COMMITTEES OF ASCO, AND VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AS WELL AS APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY, SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. EMERITUS MEMBERS WHO WERE PREVIOUSLY ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBERS RETAIN ALL THE RIGHTS AND PRIVILEGES OF ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBER STATUS RESPECTIVELY. 3. HONORARY MEMBERS. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 3.B. RIGHTS OF HONORARY MEMBERS INCLUDE HAVING ALL PRIVILEGES OF FULL MEMBERS, EXCEPT THEY MAY NOT HOLD OFFICE, INCLUDING THE RIGHT TO ATTEND MEETINGS, SERVE ON ALL COMMITTEES OF ASCO, AND VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AS WELL AS APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY, SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S GOVERNING DOCUMENTS MAY ONLY BE AMENDED WITH THE APPROVAL OF THE MEMBERS ENTITLED TO VOTE, AND THE ORGANIZATION MAY ONLY BE DISSOLVED WITH THE APPROVAL OF THE MEMBERS ENTITLED TO VOTE. THE CATEGORIES OF MEMBERS WHO ARE ENTITLED TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS PROVIDED, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS IN ONCOLOGY, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF); THE PRESIDENT OF ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM AND D/B/A CANCERLINQ); AND THE PRESIDENT OF ASCO LEASING LLC. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW,RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2013. VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP/GC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2013. CHIEF FINANCIAL OFFICER (CFO): THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2013. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF): THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2013. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY: THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2013. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, AND WAS PUBLISHED IN THE APRIL 2014 EDITION OF JOURNAL OF CLINICAL ONCOLOGY (THE EDITION IS AVAILABLE TO THE PUBLIC FOR FREE). ALL OF ASCO'S CONFLICT OF INTEREST POLICIES ARE PUBLICLY AVAILABLE. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 10B: ALTHOUGH ASCO HAS STATE AND REGIONAL AFFILIATES THROUGH ITS STATE AND REGIONAL AFFILIATE PROGRAM, ASCO DOES NOT HAVE THE LEGAL AUTHORITY TO EXERCISE SUPERVISION AND CONTROL OVER THEM AND EACH AFFILIATE IS A SEPARATELY INCORPORATED LEGAL ENTITY THAT IS RESPONSIBLE FOR ITS OWN FISCAL MANAGEMENT. AFFILIATES MAY NOT ACT ON BEHALF OF ASCO AND ARE PROHIBITED FROM ANY ACTION THAT MIGHT IMPLY AN AGENCY RELATIONSHIP. AFFILIATES MAY NOT BIND ASCO TO ANY CONTRACT WITH A THIRD PARTY. ASCO'S STATE AND REGIONAL AFFILIATE PROGRAM IS DESIGNED TO ASSIST STATE AND REGIONAL SOCIETIES IN ADDRESSING THE PRACTICAL ISSUES FACING PHYSICIANS WHO CARE FOR PEOPLE WITH CANCER AND TO FACILITATE AND ENCOURAGE INVOLVEMENT IN ASCO'S PUBLIC POLICY INITIATIVES. EACH AFFILIATE HAS A VOTING REPRESENTATIVE ON THE ASCO STATE AFFILIATE COUNCIL, WHICH IS INTENDED TO ADDRESS THE PRACTICE OF ONCOLOGY, WITH A PARTICULAR FOCUS ON REIMBURSEMENT FOR, ACCESS TO, AND QUALITY OF MEDICAL ONCOLOGY SERVICES. THROUGH PARTICIPATION IN THE ASCO STATE AFFILIATE COUNCIL, AFFILIATES HAVE A ROLE IN THE DEVELOPMENT OF PUBLIC POLICY POSITIONS AT THE NATIONAL LEVEL AND ALSO RECEIVES INPUT REGARDING STATE AND REGIONAL ISSUES AFFECTING ONCOLOGY. STATE AND REGIONAL SOCIETIES INTERESTED IN BEING AFFILIATES MUST SUBMIT AN APPLICATION TO ASCO THAT, AMONG OTHER THINGS, REQUIRES THEM TO DEMONSTRATE THAT THEY ARE VALIDLY INCORPORATED UNDER STATE LAW, HAVE IN PLACE GOVERNANCE PRACTICES AND PROCEDURES (BYLAWS, OFFICERS, DIRECTORS, ELECTIONS, MEETINGS, AND RESPONSIBLE FISCAL MANAGEMENT), AND HAVE PHYSICIAN MEMBERSHIP REQUIREMENTS THAT ARE CONSISTENT WITH ASCO'S STANDARDS. ASCO PROVIDES STATE AFFILIATES WITH A VARIETY OF ASSISTANCE, INCLUDING ASCO POLICY ANALYSES, ACCESS TO ASCO STAFF ON MATTERS OF INTEREST TO STATE AFFILIATES, AND ASSISTANCE WITH MEDIA AND OUTREACH. FORM 990, PART IX, LINE 11G COMMISSIONS: PROGRAM SERVICE EXPENSES 2,767,062. MANAGEMENT AND GENERAL EXPENSES 50,675. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,817,737. PUBLIC RELATIONS COORDINATOR: PROGRAM SERVICE EXPENSES 1,064,805. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,064,805. OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 5,924,623. MANAGEMENT AND GENERAL EXPENSES 1,105,822. FUNDRAISING EXPENSES 35,293. TOTAL EXPENSES 7,065,738. FORM 990, PART XI, LINE 9: GAIN ON VALUE OF INTEREST RATE SWAP 8,053,899. ASCO INSTITUTE FOR QUALITY LLC (FMRLY INST CLINICAL EXCELLENCE) 2318 MILL ROAD ALEXANDRIA VA 22314 271629211 QOPI CERTIFICATION PROGAM VA 233885 399873 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ASCO LEASING LLC 2318 MILL ROAD ALEXANDRIA VA 22314 273378225 RENTAL OF 5TH FLOOR VA 971631 318605 AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQUER CANCER FOUNDATION OF ASCO (CCF) 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 DEDICATED TO CONQUERING CANCER WORLDWIDE BY FUNDING RESEARCH VA 501 (C)(3) 509 (A)(1) 1 1 1 1 0 1 0 0 0 0 1 0 0 1 1 1 1 1 0 0 CCF A 295032 FMV CCF B 140000 FMV CCF C 8371709 FMV CCF E 64000000 FMV CCF J 295032 FMV CCF M 1740661 FMV CCF O 3085127 FMV CCF P 2199996 V CCF Q 5062919 FMV